O. Butt

278O Preliminary results of a phase II study of retifanlimab (PD-1 inhibitor) plus or minus epacadostat (IDO1 inhibitor) in combination with bevacizumab and hypofractionated radiotherapy for recurrent glioblastoma: NCT03532295

R. Strowd, M. Chheda, T. Johanns, 2022, Annals of Oncology.